Ana Oaknin

44PUBLICATIONS
327CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targetsPredictive and prognostic markersSocial epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Oct 22, 2026
Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.

|Sep 29, 2026
Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery.

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Apr 09, 2026
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno

|Sep 19, 2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.

Munetaka Takekuma, Shin Nishio, Satoshi Yamaguchi

Pageof 8

Frequent Collaborators

9 joint publications

Susana N Banerjee

8 joint publications

Toon Van Gorp

7 joint publications

Domenica Lorusso

7 joint publications

Nicoletta Colombo